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Abstract
Background: Infants with severe respiratory syncytial virus (RSV) bronchiolitis
have an increased risk of recurrent wheezing and asthma. We aimed to evaluate
the relationships between regulatory T cell (Treg) percentage and cytokine
production of in vitro‐stimulated CD4+ T cells during acute bronchiolitis and
the development of recurrent wheezing in the first 3 years of life.
Methods: We obtained peripheral blood from 166 infants hospitalized with their
first episode of RSV‐confirmed bronchiolitis. Granzyme B (GZB) expression, and
interleukin‐10, interferon‐γ, tumor necrosis factor‐α (TNF‐α), IL‐4, and IL‐5
production by in vitro anti‐CD3/CD28‐ and anti‐CD3/CD46‐activated CD4+ T
cells, and percentage of peripheral Treg (CD4+CD25hiFoxp3hi) cells were measured
by flow cytometry. Wheezing was assessed every 6 months. Recurrent wheezing
was defined as three or more episodes following the initial RSV bronchiolitis.
Results: Sixty‐seven percent (n= 111) of children had wheezing after their initial
RSV infection, with 30% having recurrent wheezing. The percentage of peripheral
Treg (CD4+CD25hiFoxp3hi) cells was not significantly different between the
wheezing groups. Decreased TNF‐α production from anti‐CD3/CD28− and anti‐
CD3/CD46− activated CD4+ T cells was observed in the recurrent wheezers,
compared with nonwheezers (p= .048 and .03, respectively). There were no
significant differences in the GZB+ CD4+ T cells and production of other
inflammatory cytokines between these groups.
Conclusions: We demonstrated lower TNF‐α production by in vitro stimulated
CD4+ T cells during severe RSV bronchiolitis in children that subsequently
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developed recurrent wheezing, compared with children with no subsequent
wheeze. These findings support the role of CD4+ T cell immunity in the
development of subsequent wheezing in these children.
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1 | INTRODUCTION
Respiratory syncytial virus (RSV) bronchiolitis is a
common cause of lower respiratory tract infection in
infancy. Almost all children demonstrate seropositivity to
RSV by age 2 years.1 Severe RSV bronchiolitis is
associated with the subsequent development of recurrent
wheezing, physician‐diagnosed asthma, and decreased
lung function later in life.2,3
The pathogenesis of recurrent wheezing and asthma
following severe RSV bronchiolitis remains unclear.
There appears to be a role of CD4+ T cells in mediating
lung inflammation and pathology in RSV‐infected
mice.4,5 Immune dysregulation with an imbalance of
Th1 and Th2 responses has been demonstrated in RSV‐
infected mice and children.6-8 A recent study demon-
strated that higher Th2 and Th17 cytokine levels in
nasal wash samples obtained during acute RSV
bronchiolitis were associated with recurrent wheezing
at age one and 2 years.9
As Foxp3+ regulatory T cells (Tregs) play an
important role in maintaining the homeostasis of the
immune system,10,11 as well as limiting the inflammatory
response in the lungs during the acute phase of RSV
bronchiolitis, 12-14 we hypothesized that the frequency of
circulating Tregs might differ in those children subse-
quently developing recurrent wheezing. It has been
demonstrated that infants hospitalized with severe RSV
bronchiolitis have a reduction in circulating Tregs,
though subsequent outcomes are unknown.15
In this study, the CD4+ T cells were stimulated in two
conditions by using anti‐CD3/CD28 and anti‐CD3/CD46.
As demonstrated in previous studies, human T cells with
a Tr1‐like regulatory phenotype and Th1‐like cells can be
induced in vitro by coengagement of CD3 and CD46 on
CD4+ T cells, in the presence of high IL‐2, resulting in
interleukin‐10 (IL‐10) secretion and expression of gran-
zyme B (GZB).16-19
The purpose of this study was to evaluate a putative
relationship between circulating Foxp3+ Tregs and
cytokine production of in vitro activated CD4+ T cells
in infants with acute severe RSV bronchiolitis and the




Peripheral blood samples were available from a subset of
179 children in a cohort of 209 children that participated in
the RSV bronchiolitis in early life (RBEL)‐2 study. As
previously reported,3 this prospective cohort of children 12
months old had their first episode of wheezing (documen-
ted by a physician) with a nasopharygeal swab positive for
RSV and had bronchiolitis severe enough to require
emergency department care or hospitalization. Exclusion
criteria were a history of preterm birth at less than 36 weeks
of estimated gestational age, previous wheezing or a
diagnosis of asthma, congenital abnormalities of the heart
and lung, cystic fibrosis diagnosed in the patient or
immediate family, regular use of antigastroesophageal
reflux medication, bronchodilators or anti‐inflammatory
medications, and coinfection with other organisms. Thirty
children did not have blood available for studies due to
reasons that included difficult blood draws, parental refusal
of blood draw attempts, or insufficient blood. Informed
consent was obtained from the parents/legal guardian and
approved by the Washington University Medical Center
Institutional Review Board.
2.2 | Wheezing outcomes
The parents or legal guardians of the children were
contacted at 6‐month intervals by telephone to assess the
occurrence of wheezing episodes in the child. We defined
the occurrence of a wheezing episode each time a parent/
guardian answered yes to either “Has your child had
wheezing with colds?” or “Has your child had wheezing
without colds?” during a follow‐up contact.3
2.3 | Identification of Tregs
(CD4+CD25hiFoxp3hi cells) in peripheral
blood
Tregs (CD4+CD25hiFoxp3hi cells)were identified by the
Human Regulator T‐cell Whole Blood Staining Kit. Briefly,
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100 μL of fresh whole blood was incubated with
fluorophore‐labeled mAbs to CD4 and CD25, followed by
fixation/permeabilization. Cells were washed and incubated
with anti‐human Foxp3 or IgG isotype control. Labeled cells
were identified on a four‐color cytometer (BD FACSCaliber)
followed by analysis on Flowjo (v9.2). To differentiate
between activated T cells that also express CD25 and Foxp3
and Tregs, we analyzed the CD4+CD25hiFoxp3hi cells by
gating on CD4 expression followed by CD25hi and Foxp3hi
expression. Tregs are presented as the percentage of CD4+
cells. See Supporting Information materials for the anti-
bodies, media, and reagents used in the experiments.
2.4 | Assay for CD3/CD28− and
CD3/CD46‐activated CD4+ T cells
2.4.1 | Purification and in vitro
stimulation of CD4+ lymphocytes
PBMC were isolated as previously performed20 and
resuspended in complete Roswell Park Memorial In-
stitute Medium (RPMI; 10% fetal calf serum [FCS],
L‐glutamine, 50 U penicillin‐50 μg streptomycin/mL and
at 1.5 × 106 cells/mL. CD4+ T lymphocytes were isolated
by magnetic bead separation using a CD4+ isolation kit
according to manufacturers’ protocol. Purity of CD4+ T
cells was greater than 85% as determined by fluorescence‐
activated cell sorting (FACS) and viability was greater
than 80% as assessed by trypan blue exclusion.
Purified CD4+ T lymphocytes (5.5 × 104 cells/well) were
added in 55 μL of culture medium, consisting of RPMI 1640
medium plus 10% FCS and 200 mM L‐glutamine in the
presence of 25 U/mL recombinant human IL‐2, placed in
384‐well plates coated with 10 μg/mL anti‐CD3 alone, 10 μg/
mL anti‐CD3, and 5 μg/mL anti‐CD28, or 10 μg/mL anti‐
CD3 and 10 μg/mL anti‐CD46 for generating Tr1 cells in
vitro as previously described,16 or phosphate‐buffered saline
(PBS) in medium plus rIL‐2 as a negative control. After 3
days, cell‐free supernatants were collected and frozen at
−80°C for batch analysis of cytokines. CD3/CD46‐activated
CD4+ T cells have a cytokine profile, IL‐10 skewed, that is
distinct from that induced by CD3/CD28 stimulation but
similar to Tr1 cells as previously described.16 After in vitro
stimulation, cells were immediately analyzed by flow
cytometry for GZB expression.
2.5 | Th1/Th2 cytokine analyses
Supernatants from 3‐day cultures were thawed and batch
analyzed for IL‐10, IL‐2, IL‐4, IL‐5, tumor necrosis factor‐
α (TNF‐α), and interferon‐γ (IFN‐γ) using the Human
Th1/Th2 cytometric bead array kit. Limits of detection of
the assay are provided in the Supporting Information
materials. Briefly, in 96‐well plates, 25 μL of supernatant
was diluted 1:2 followed by the addition of capture beads
and subsequent PE detection reagent. After 3 hours of
incubation at room temperature, the beads were washed,
resuspended in wash buffer and transferred to FACS
tubes. Data collection was performed on FACSCalibur
flow cytometry. Data analysis was performed using FCAP
Array Software v3 (BD Biosciences).
2.6 | GZB analysis
After 3 days of culture and in vitro stimulation of CD4+
cells with monoclonal antibodies (mAb) to CD3 and CD46
or to CD3 and CD28 or to CD3 alone, in the presence of
IL‐2, cells were harvested and resuspended in PBS plus
ethylenediaminetetraacetic acid solution, labeled with
fluorescein isothiocyanate‐conjugated anti‐GZB Ab or
isotype control then analyzed by a four‐color FACSCalibur
flow cytometry using CellQuest™Pro version 5.2.1
(Becton‐Dickinson Corporation, Mountain View, CA).
Results are reported as the percentage of CD4+ cells.
2.7 | Statistical analysis
Data are reported in mean ± SD’s or percentages for
frequencies. Results are reported in pg/mL for cytokines
and mean percent of CD4+ cells for GZB expression.
Cytokine level from CD4+ T cell cultures was calculated
by subtracting the value of a nonstimulated well with
RPMI from the well stimulated with CD3/46 or CD3/28
and then log‐transformed. Groups were compared using
analysis of variance, t tests, and χ2 where appropriate. A
P value less than .05 was considered statistically significant.
For the comparison on participants’ characteristics, t test or
Kruskal‐Wallis and χ2 test were used with continuous and
categorical variables, respectively. For continuous variables,
we used Shapiro‐Wilk test to assess the normality of
data distribution. Immunoglobulin E levels were log‐
transformed. The statistical analyses were performed using
SAS software, version 9.3 (SAS Institute, Cary, NC).
3 | RESULTS
3.1 | Demographics and wheezing
episodes
Of 209 children enrolled in the RBEL‐2 cohort, 179
(85.6%) had blood drawn at entry (Figure S1). Children
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who did not have blood draws for the study did not
differ from those with blood draws in terms of their
baseline characteristics and bronchiolitis severity
(Table S1). Of these 179 children, 166 (93%) subjects
had adequate follow‐up data available to evaluate
wheezing outcomes. Of 166 children, 160 (96%) were
hospitalized and the rest required only treatment in the
emergency room. The average age of entry to the study
was 4.2 ± 2.9 months and the average age at follow‐up
was 28.8 ± 15.6 months. Approximately half of the
cohort were Caucasians and 60% were male. Majority of
children in this cohort are from atopic family with 80%
had first‐degree relatives with atopic diseases. During
the first 3 years of life, 111 (67%) children experienced at
least one wheezing episode; 35 (21%) had one wheezing
episode, 26 (16%) had two wheezing episodes and 50
(30%) had recurrent wheezing defined as three or more
episodes. Compared to children with no subsequent
wheezing, the recurrent wheezing group had a higher
proportion of males and non‐Caucasian races (Table 1).
The recurrent wheezing group had a longer duration of
follow‐up (31.3 ± 11.9 vs 23.1 ± 16.8 months, P = .007)
and a shorter duration of maternal pregnancy (38.7 ± 1.2
weeks in recurrent wheezing group vs 39.0 ± 1.2 weeks
in no wheezing group, P = .01). Due to differences in
gender, race, and duration of follow‐up between the
wheezing groups which potentially confound the wheez-
ing outcomes, these variables were included as covari-
ates in the analysis of the primary outcome of the study.
The overall prevalence of physician‐diagnosed asthma
was 15%, and the recurrent wheezing group had a
significantly higher prevalence of MD‐diagnosed asthma
compared to the no wheezing group (34% vs 2%, P <
.0001). The average duration between the onset of
bronchiolitis symptoms and blood collection was 3.5 ±
1.9 days. There were no differences on the timing of
blood collection among wheezing groups (Tables 1 and
S2).
TABLE 1 Characteristics and wheezing outcome of children following severe RSV bronchiolitis during infancy





P value (No vs ≥3
wheezing)
Demographics
Age at RSV (study entry), m 4.2 ± 2.9 3.9 ± 3.1 4.3 ± 2.8 0.2
Age at follow‐up, m 28.8 ± 15.6 26.4 ± 18.0 34.8 ± 12.0 0.01
Duration of follow‐up, m 24.7 ± 15.1 23.1 ± 16.8 31.1 ± 11.9 0.01
Male sex, % 98 (59.0) 27 (49.0) 35 (70.0) 0.03
Caucasians, % 77 (46.3) 32 (58.1) 19 (38.0) 0.04
Pregnancy history
Duration of pregnancy, w 38.7 ± 1.3 39.0 ± 1.2 38.4 ± 1.2 0.01
Birth weight, g 3300 ± 473 3379 ± 420 3257 ± 518 0.2
Birth length, cm 50.4 ± 2.9 50.2 ± 3.1 50.7 ± 2.9 0.6
Hospitalization data
Length of stay, d 3.8 ± 2.0 3.7 ± 1.8 4.0 ± 2.5 1.0
Lowest SaO2, % 90.7 ± 5.4 91.0 ± 4.4 90.4 ± 7.2 0.4
Bronchiolitis severity score 7.5 ± 2.2 7.4 ± 2.1 7.3 ± 2.2 0.9
Durationbetween onset of symptoms
and blood draw, days
3.5 ± 2.9 3.2 ± 2.7 3.1 ± 2.6 0.9
Family history
History of first‐degree relatives with
asthma, %
84 (50.9) 22 (40.0) 27 (55.1) 0.1
History of first‐degree relatives with
atopic diseases, %
135 (81.8) 42 (76.3) 40 (81.6) 0.5
Other histories and exposures
Personal history of eczema 22 (13.4) 6 (10.9) 10 (20.4) 0.2
Intraute rine exposure to cigarette
smokes
41 (24.8) 17 (31.4) 10 (20.0) 0.2
Postnatal exposure to cigarette smoke 82 (49.4) 25 (45.4) 26 (52.0) 0.5
History of daycare attendance 50 (30.1) 17 (30.9) 13 (26.0) 0.6
Laboratory tests at baseline
Baseline IgE (IU/mL) (n = 95) 32 ± 116 36 ± 107 22 ± 60 0.4
Baseline eosinophils (%) (n = 87) 1.5 ± 1.8 1.6 ± 2.6 1.3 ± 1.2 0.7
Note: Data are expressed as means ± SDs, except as noted.
Abbreviations: IgE, immunoglobulin E; RSV, respiratory syncytial virus.
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3.2 | Percent of Tregs
(CD4+CD25hiFoxp3hi) cells in blood during
acute illness in the recurrent wheezing
group
The average percentage of CD4+CD25hiFoxp3hi cells in
peripheral blood was 0.99 ± 0.51% CD4+ cells for recurrent
wheezers and 1.07 ± 0.54% CD4+ cells for never wheezers
(Table 2). Even after adjustment for covariates of age at
follow‐up, gender, and race, there was no statistical
difference in children with recurrent wheezing compared
to never wheezers. As activated CD4+ T cells also express
CD25, the IL‐2R, and Foxp3, the overall percentage of
CD4+CD25+Foxp3+ T cells in recurrent wheezers vs never
wheezers were assessed. Never wheezers had slightly
increased CD4+CD25+Foxp3+ T cells (5.9 ± 2.3% CD4+
cells) compared to wheezers (5.0 ± 1.9% CD4+ cells, P =
.051) which became significant after adjustment for
covariates; P = .03.
3.3 | Decreased TNF‐α production by in
vitro CD3/CD28‐activated CD4+ T cells and
CD3/CD46‐activated CD4+ T‐cells in the
recurrent wheezing group
The percentage of CD3/CD46‐activated CD4+ T cells,
expressed as % of CD4+ T cells that are positive for GZB
was lower in the recurrent wheezing group compared to
never wheezers (10.4 ± 13.6 vs 18.7 ± 17.6% CD4+ cells,
P = .009; Figure 1 and Table 2). However, after adjustment
for covariates, this was not statistically different (P = .08).
CD3/CD46‐activated CD4+ T cells from children in the
recurrent wheezing group produced lower levels of TNF‐α
than never wheezers (155 ± 237 vs 354 ± 454 pg/mL; P = .01
unadjusted, P = .048 adjusted). Diminished TNF‐α produc-
tion was observed between any wheezers relative to never
wheezers (P = .01, Table S3). IL‐10 and IFN‐γ production did
not significantly differ between the recurrent wheezing group
and the non‐wheezing group. The production of IL‐10, IL‐4,
and IL‐5 from CD3/CD46‐activated CD4+ T cells did not
significantly differ by wheezing category.
CD3/CD28‐activated CD4+ T cells also produced sig-
nificantly less TNF‐α in the recurrent wheezing group
compared to never wheezers (142 ± 280 vs 240 ± 328 pg/
mL; P = .009 unadjusted, P = .03 adjusted), Table 2. Similar
trends were observed between never wheezers and any
wheezers (240 ± 328 vs 146 ± 254 pg/mL, P = .02). There
were no differences between the groups in production of
cytokines, including IFN‐γ, IL‐10, IL‐4, and IL‐5.
4 | DISCUSSION
Although it is known that infants with severe RSV
bronchiolitis have increased risks of recurrent wheezing
and asthma in later life, previous literature on roles of innate
and adaptive cytokines in the pathogenesis of subsequent
wheeze following acute severe RSV bronchiolitis have been
limited.9 In our study, we have demonstrated impaired
TABLE 2 Peripheral blood CD4+CD25hiFoxp3hi cells and granzyme B expression and cytokine production from CD3/CD46‐activated
and CD3/CD28‐activated CD4+ cells during severe RSV bronchiolitis in infancy by wheezing outcome
No wheezing ≥3 wheezing episodes Unadjusted P valuea Adjusted P valueb
CD4+CD25hiFoxp3hi cells (N = 101, no wheezing n = 52, ≥3 wheezing n = 49)
% CD4+ cells 1.07 ± 0.54 0.99 ± 0.51 0.6 0.5
CD3/CD46‐activated CD4+ T cells (N = 104, no wheezing n = 50, ≥3 wheezing n = 44)
Granzyme B (% CD4+) 18.7 ± 17.6 10.4 ± 13.6 0.009 0.08
IL‐10, pg/mL 178 ± 323 100 ± 245 0.2 0.5
TNF‐α, pg/mL 354 ± 454 155 ± 237 0.01 0.048
IFN‐γ, pg/mL 881 ± 3,326 1,362 ± 3,605 0.5 0.6
IL‐5, pg/mL 86.6 ± 270 55.0 ± 148 1.0 0.8
IL‐4, pg/ml 2.6 ± 4.2 2.0 ± 2.7 0.8 0.3
CD3/CD28‐activated CD4+ T cells (N = 104, no wheezing n = 50, ≥3 wheezing n = 44)
Granzyme B (% CD4+) 6.8 ± 8.0 5.3 ± 8.0 0.3 0.4
IL‐10, pg/mL 64.4 ± 114 51.5 ± 109 0.2 0.3
TNF‐α, pg/mL 239 ± 328 142 ± 280 0.009 0.03
IFN‐γ, pg/mL 1,263 ± 1,488 1,488 ± 3,397 0.5 0.5
IL‐5, pg/mL 106 ± 313 80.6 ± 141 0.7 0.9
IL‐4, pg/mL 2.8 ± 3.2 3.5 ± 3.5 0.4 0.9
Note: Data were subtracted from negative control conditions (PBS) and negative data were adjusted to zero, then log‐transformed for statistical analysis.
Abbreviations: IFN‐γ, interferon‐γ; IL, Interleukin; TNF‐α, tumor necrosis factor‐α.
aComparison between no wheezing and ≥3 wheezing episodes.
bAdjusting variables including age at follow‐up, race, and gender.
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TNF‐α production from in vitro CD3/CD28‐activated CD4+
T cells and CD3/CD46‐activated CD4+ T cells during acute
illness in children who developed recurrent wheezing
following severe RSV bronchiolitis. Previous studies in
humans were performed to describe the cytokine profiles
during RSV bronchiolitis compared to normal controls or
other types of respiratory viruses, or to evaluate the
association of cytokine profiles and the severity of RSV
bronchiolitis in young children; and the findings from prior
studies suggest a role for CD4+ T cells in the airway
inflammation in these children.8,20-26 However, the results
on the Th1/Th2 imbalance is conflicting with no mechan-
istic data for the production of cytokines after in vitro
stimulation of CD4+ T cells followed by correlation to
wheezing outcomes presented. We previously showed that
severe RSV infection in early life was associated with a high
incidence of asthma and eczema; however, it was not
associated with a Th2 phenotype in the peripheral blood.27
A recent birth cohort study by Turi, et al have demonstrated
infants who are at increased risks for recurrent wheeze in
the first and second year following acute RSV infection had
a unique pattern of nasal immune response characterized by
lower non‐IFN antiviral immune‐response mediators in-
cluding TNF‐α and higher type‐2 and type‐17 cytokines.9
TNF‐α is a proinflammatory cytokine that plays roles
in neutrophil and eosinophil recruitment to the airway.28
Higher TNF‐α levels in airway secretions have been
observed in mice and human with RSV infection.7,29
However, it has been shown that lower blood TNF‐α
levels in infants with RSV bronchiolitis were associated
with greater disease severity and a longer hospital
stay.24,30 Our finding is consistent with the study by Turi
et al9 evaluating nasal immune response phenotypes in
infants with RSV infection in which they demonstrated
low non‐IFN antiviral immune response, including TNF‐
α, as significantly associated with recurrent wheezing in
the first and second‐year following RSV infection. In the
upper airways, a decrease in IL‐10 potentiates an increase
in the TNF‐α response which controls the viral infec-
tion.31 As diminished TNF‐α observed in recurrent
wheezers after both stimulation conditions from periph-
eral blood‐derived CD4+ T cells and the significant
differences in the levels of TNF‐α among four wheezing
categories, evidence suggests that (a) CD4+ T cells may
be impaired in their production of TNF‐α during RSV
infection and (b) TNF‐α may play roles in the pathogen-
esis of airway inflammation and subsequent wheezing
following severe RSV bronchiolitis in children.
FIGURE 1 Granzyme B expression and cytokine productions by CD3/CD46‐activated CD4+ T cells in vitro in no wheezing and
recurrent wheezing groups. *Bar graphs with mean ± one standard error are shown. Data were subtracted from negative control conditions,
and log‐transformed for statistical analysis. IFN‐γ, interferon‐γ; IL, Interleukin; TNF‐α, tumor necrosis factor‐α
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We did not discern a difference in IFN‐γ levels between
the wheezing groups after in vitro stimulation which is
consistent with our previous study.27 The data on the role
of IFN‐γ in RSV infection are conflicting. The IFN‐γ
response in children less than 6 months old have a
reduced IFN‐γ response which contributes to the increased
incidence of RSV in the younger age group.31 One study
has shown that IFN‐γ in nasal secretions might be
protective of disease severity in RSV bronchiolitis32,33;
however, the opposite was seen in a larger cohort.34
The Th2 response in RSV is required for antibody
production and to limit Th1 induced inflammation.5
Although studies in mice have demonstrated an im-
portant role for IL‐10 in limiting lung inflammation in
RSV bronchiolitis,35,36 the current evidence on the
protective role of IL‐10 in RSV‐infected humans is
conflicting.5,37,38 The production of IL‐10, IL‐4, and IL‐5
from in vitro stimulated T‐cells in our study was not
statistically different between nonwheezers and whee-
zers, consistent with prior studies. Further understanding
mechanisms of the immune response to RSV infection
that lead to the development of recurrent wheezing and
asthma in these children especially in the lung and
airways where the virus resides is needed.
Granzymes are proteinases that are expressed by
various immune cells including T cells.39,40 Children
with severe RSV bronchiolitis have increased the
production of granzymes from immune cells,41 and Tregs
help control lung inflammation during RSV infection in a
GZB‐dependent manner.42 However, after adjusting with
covariates, we did not find a significant difference in the
percentage of GZB+CD4+T cells after in vitro stimula-
tion of CD4+ T cells between the recurrent wheezing
group and those who never wheezed.
The percentage of peripheral Tregs (CD4+CD25hiFox-
p3hi) cells in children in our cohort is comparable to a
previous report.43 The percentage of Tregs in adult
humans represent 4% to 10% of CD4+ T cells, while this
percentage decreases in children, suggesting that small
changes can have dramatic impacts on immune func-
tion.44 Previous studies have demonstrated that host T
cell responses play a role in causing lung pathology
following RSV bronchiolitis.12,35 We did find a small
reduction in the number of CD4+CD25+Foxp3+ acti-
vated cells in children with recurrent wheezing, com-
pared to children who never wheezed. The slight
reduction in both Treg (CD4+CD25hiFoxp3hi) and
activated CD4+CD25+Foxp3+ T cells could be due to a
recruitment of these cells to airway, apoptosis or their
plasticity in these children with acute severe RSV
bronchiolitis. Although this could reflect the severity of
infection, we did not find significant differences in
bronchiolitis severity (as measured by bronchiolitis
severity scores, lowest saturation during hospitalization
and duration of hospital stay) and wheezing outcome in
this cohort, Table 1. Although there was a statistical
difference between the percentage of activated T cells
(CD4+CD25+Foxp3+) cells between the recurrent
wheezing group and non‐wheezing group, the percentage
change is small. The lower percentage of activated T cells
(CD4+CD25+Foxp3+) in the recurrent wheezers com-
pared to those whom never wheezed is consistent with
the lower TNF‐α secretion upon in vitro stimulation in
these children. However, functional studies of these
T‐cells should be performed in a future cohort as the
suppressive function and cytokine profile could be
impaired despite the similar percentage of CD4+ T cells.
Our cohort has several unique characteristics. It is one
of the largest prospective cohorts in children with severe
RSV bronchiolitis in infancy with comprehensive charac-
terization at baseline, regular follow‐up visits, even
distribution among Caucasians and African‐Americans,
and a high retention rate of 92%. In this cohort, the
majority of children with acute severe RSV bronchiolitis in
infancy developed subsequent wheezing and approximately
one‐third experienced recurrent wheezing. Our findings are
consistent with previous studies indicating that wheezing is
a common outcome in children with a history of severe
RSV bronchiolitis.45,46 Due to a lack of objective measure-
ment for asthma in young children, and because recurrent
wheezing is a finding closely associated with the diagnosis
of asthma, it was used as the primary outcome in our study.
Limitations of the present study include the fact that
experiments for CD4+ T cells were performed in vitro on
peripheral blood‐derived cells and this might not reflect
biological phenomena occurring in vivo, especially at the
site of RSV infection like the lung and upper airways.
Although T cells from the airways might better reflect lung
pathology, we could not obtain lung specimens from these
infants without risks. We also did not obtain specimens
from age‐matched normal controls for comparison, as
RBEL is a prospective observational cohort of children
exposed to severe RSV allowing us to use children who did
not develop recurrent wheezing as a comparison group. We
also did not assess baseline CD4+ cell phenotype and
function before RSV bronchiolitis as this was not a birth
cohort. As the recurrent wheezers had a significant longer
period of follow‐up, it is possible that the never wheezers
could develop wheezing later in life. The wheezing
outcomes were assessed by telephone interview, so this
may not be an accurate parameter of the outcome.
However, wheezing is a common outcome used in a
number of studies as the majority of these wheezing
episodes may not require medical attention.9,47 Due to the
limitation of blood that we can draw from infants, we did
not measure the plasma cytokines in our subjects to
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determine the correlation with the in vitro CD4+ functional
measures and did not have an adequate data to provide
additional insights into the kinetics of these cytokines. The
limited volume of blood in infants also prevented absolute
cell counts from being determined. Additional T cell
populations and cytokines could play an important role
in the T cell‐dependent response during airway inflamma-
tion and exacerbation of bronchial asthma in this popula-
tion.48,49 Lastly, as the cytokines measured in the study are
certainly correlated, the significant finding could be a result
of multiple comparisons, so the studies should be repeated
in a different, preferably larger cohort.
In summary, we have demonstrated lower TNF‐α
production by in vitro stimulated CD4+ T cells during
severe RSV bronchiolitis in children who subsequently
developed recurrent wheezing in the first 3 years of life.
This supports the role of CD4+ T‐cell immunity in the
development of recurrent wheezing in these children.
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